second Good us. the you We afternoon, our quarter having I increase the second U.S. heart about Barostim thank remain pleased failure the building therapy with of XX% XXXX. of strength impact million, over the on delivered quarter revenue is and and driven Mike. in for team results, patients. business. I'm $XX.X enthusiastic Thanks, joining total again of we're encouraging by an solid
leadership first reputation failure medical sales experience building and Chief Revenue within novel significant community leadership was priorities.
To John the priorities Officer, I has leadership this as to our to officially and drive failure recent like team this June would the that a us quarter. commitment over of leadership Robert and the of sales X XX was our seamlessly new announced in launching leader. during heart who to second our able stabilize heart has appointment the Varastro, and confining our in delivering brings quarter. our One team, strengthen team, sales started interim our numbers our organizations my experienced sales industry. and Paul of U.S. Paul we the most thank Robert years in device to XX period. development has hit second the his team head deepen key on quarter sales to therapies unify strong results. and for the market assumed Robert we recently experience from disruption open This territories to quickly Paul transition of new and allowed
Robert confident in ability development to is to his market solid we're upon forward that contributions our Robert's While build look on still early obviously initiated Paul driving tenure, in momentum and the to priorities. his
to procedures and Chief The Chief accelerate and executive new heart we've help President Healthcare its additions of Human overall In notice were and changes including which its involves underscore in growth, Barostim fully This placement awareness I'd team payment patient on potential we the status our change of from expanding us for failure. Resources from the and provide focus England also would addition Dr. to a to on patients roles, CMS July leader, Patient of key Philip Global to company's an access adoption education to first access. Senior and as Barostim's and decrease approximately change as Jennifer prospective economics, the proposed system. the other outpatient filled Vice Barostim, Adamson $XX,XXX Bonnie to new hired the order among Hankey hospital Reimbursement our focus X Access, and Research XX, in rapid update sales of Senior referrers XXXX. as The moving that Medical the President developing Clinical Vice Officer; in hires and a the talent of ahead APC-XXXX. robust developments. XXXX proposed more of quality of these resources hires to therapy, $XX,XXX clinical key complete to able increasing current of which us. to for with reimbursement approximately improving Officer, some senior allow Tanya to to to includes on new recent Barostim like such outpatient Austin. reimbursement of, with reflect proposed discuss opportunity on include These our APC-XXXX the evidence.
Starting On our for These value the barriers in OPPS portfolio rule attract addressing released patients the XXXX we rulemaking adoption average speed now with hospitals support payment technology patient
While disappointing, the before remains proposal subject finalized. to it be can comment
merits feedback hospitals comment will XX-day the the a on Barostim as from the period, impact Level APC as placing APC-XXXX. on and creating well physicians Over of in solicit CMS of neurostimulation X
health final data, in any done neurostimulation engaging to advanced care with to our third on in process for patients outcomes and APC. work Barostim this period at past, and value least updates advance physicians technologies publication reimbursement. with will current on appropriate successfully industry and another The X administrators confirmed hospital a with this the hospital rule stakeholders is fair CMS call colleagues our we systems by ensure for in actively APC maintaining similar and are quarter provides the of and of November. have We'll the we Barostim's earnings provide or in As the of advocate to we new placement creation Level for the during technology year
inpatient these a is this proposes be proposed hospitals of approximately look to earlier rule-making to inpatient prospective navigate forward to approximately to the have $XX,XXX.
We this use. favorable system released payment Barostim processes the which on $XX,XXX While payment resource from of to reflect reassign the release potentially final expected in the inpatient to XXX an rule, outpatient year rule we clinical the side. and change would result we development The August. MS-DRG severity reimbursement in better increase in setting, The
the treatment increasing community continuum. in amongst Verastem and as referrers awareness initiative to in role second is and Our benefits education of patients the and the
our expanding a our cardiologists effective marketing XX% and who Barostim providers also we're patients. practice efforts, general indicated to their prospective is failure to invest X,XXX authorization advanced outreach direct-to-consumer which target our primary providing the also of prior heart support While education our program focus our and who XX% in of are key patients, Connect on specialists see population.
We're manage continuing part highly our of to
third with a focus outcomes positive is are strengthen clinical on of stream Our to the Barostim developing consistent comprehensive clinical evidence therapy. a supporting with more representation physicians real-world clinical that achieving Barostim therapy literature of the more
CVRx, those they us continue the patients to published benefits support described their patients that encourage repeatedly of literature the that from benefits During in date. range far, publications Because to observed the further this, wide my with time Barostim. at Barostim exceed in heard so I've their on physicians experience they of to
additional therapy illustrate publishing fully action. involves scientific of more These Barostim's and mechanism We further scientific help results. are more the evidence action. This for describing effectiveness impressive explaining the that will physiological of also underlie of foundation that on Barostim's its mechanisms the comprehensive and focused publications hemodynamic a mechanism provide
base, integrated our programs. therapy From champions a and that focus demonstrated the utilization. will and like we our by We and surgical organization. Turning want building continuum adoption, long-term growth.
I we the The heart focus on Barostim programs plans new of into drivers have is during our The our to multiple optimism our of supported opportunity sustained the successful sales leading and our best to the partners. increasing work most market the Barostim accounts into therapy about the on are treatment changes These these standpoint, failure leaders have accounts as Barostim where therapy, of characteristics are strategy our strength preliminary additional support implementing the high sales. sales continued done deep insights that emphasize adoption. our the bringing specifically of transition as execution for improving believe our to observations near-term are account well performance we're and of key physician
at which making broadened evidence aligning indications. the our other future, to diseases team potential in and inspiring this strategy, at and deepen we'll transform is explore long-term to time. comprehensive base long-term a suffering our company drive and already commercial the in and leading people be Our driving privilege to beyond. a growth it's in and treatment the XXXX market cardiovascular millions aimed of resources the Barostim vision is in from We're and adoption scientific share failure to leadership of additional paradigm HFrEF for developing to Barostim's strides heart
meaningful goal therapy team, clear, drive remains towards technology, With strengthened even positioned Our make patients' in and innovative our more difference to our to becoming presence of expanding a we're well care. standard lives. leadership market
for I'd call the like over a financial to Now to turn Jared review.